Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.
Makiko SugaKentaro FukushimaTomoaki UedaYasuyuki AraiShunsaku NakagawaYosuke MinamiJun TodaAkihisa HinoJiro FujitaTakafumi YokotaNaoki HosenPublished in: Clinical case reports (2022)
FMS-like tyrosine kinase 3-internal tandem duplication ( FLT3 -ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for FLT3 -ITD-positive AML-primary induction failure patients with central nervous system involvement.
Keyphrases
- tyrosine kinase
- acute myeloid leukemia
- poor prognosis
- stem cell transplantation
- combination therapy
- epidermal growth factor receptor
- umbilical cord
- allogeneic hematopoietic stem cell transplantation
- mesenchymal stem cells
- long non coding rna
- high dose
- cerebrospinal fluid
- bone marrow
- low dose
- radiation induced
- replacement therapy